{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:06:57Z","timestamp":1778569617389,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:23:55Z","timestamp":1758583435000},"page":"595-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updates on Diagnostic Criteria of Inclusion Body Myositis"],"prefix":"10.1016","volume":"51","author":[{"given":"Elie","family":"Naddaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2025.07.005_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JND-160198","article-title":"A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis","volume":"4","author":"Callan","year":"2017","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.005_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.410160207","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis","volume":"16","author":"Engel","year":"1984","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.005_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2025.07.005_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1020113","article-title":"Inclusion body myositis: update on the diagnostic and therapeutic landscape","volume":"13","author":"Naddaf","year":"2022","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.005_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18040","article-title":"The pursuit of diagnostic excellence","volume":"2","author":"Centor","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.005_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.005_bib7","first-page":"445","article-title":"Phenotypic spectrum of inclusion body myositis","volume":"42","author":"Roy","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.005_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1146015","article-title":"Imaging biomarkers in the idiopathic inflammatory myopathies","volume":"14","author":"Zubair","year":"2023","journal-title":"Front Neurol"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.005_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.nmd.2009.07.015","article-title":"Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype","volume":"19","author":"Mastaglia","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.005_bib10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00415-005-0884-y","article-title":"Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients","volume":"252","author":"Badrising","year":"2005","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.005_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/jnnp.2007.138891","article-title":"Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases","volume":"79","author":"Needham","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.005_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.nmd.2014.04.009","article-title":"Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials","volume":"24","author":"Hogrel","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.005_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00005792-200109000-00006","article-title":"Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period","volume":"80","author":"Felice","year":"2001","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0000000000000958","article-title":"Exploring challenges in the management and treatment of inclusion body myositis","volume":"35","author":"Skolka","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"Pt 11","key":"10.1016\/j.rdc.2025.07.005_bib15","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.rdc.2025.07.005_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-325141","article-title":"Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis","author":"Sangha","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.005_bib17","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/keab716","article-title":"Survival and associated comorbidities in inclusion body myositis","volume":"61","author":"Naddaf","year":"2022","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.005_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.005_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/art.1780300406","article-title":"Inclusion body myositis presenting as treatment-resistant polymyositis","volume":"30","author":"Calabrese","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.005_bib20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0960-8966(02)00098-6","article-title":"Inclusion body myositis: morphological clues to correct diagnosis","volume":"12","author":"Dahlbom","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"10.1016\/j.rdc.2025.07.005_bib21","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000003821","article-title":"Overlapping features of polymyositis and inclusion body myositis in HIV-Infected patients","volume":"88","author":"Lloyd","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.005_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/nan.12149","article-title":"Mitochondrial and inflammatory changes in sporadic inclusion body myositis","volume":"41","author":"Rygiel","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.005_bib23","doi-asserted-by":"crossref","first-page":"e910","DOI":"10.1212\/WNL.0000000000008863","article-title":"Granulomatosis-associated myositis: high prevalence of sporadic inclusion body myositis","volume":"94","author":"Dieudonn\u00e9","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.005_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nmd.2018.10.007","article-title":"Myopathies featuring non-caseating granulomas: sarcoidosis, inclusion body myositis and an unfolding overlap","volume":"29","author":"Alhammad","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.rdc.2025.07.005_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, hoofddorp, the Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"Pt 3","key":"10.1016\/j.rdc.2025.07.005_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.rdc.2025.07.005_bib27","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.005_bib28","first-page":"370","article-title":"Current status of clinical outcome measures in inclusion body myositis: a systematised review","volume":"41","author":"Roy","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.005_bib29","series-title":"Diagnostic criteria for neuromuscular disorders","first-page":"81","article-title":"Inclusion body myositis","author":"Verschuuren","year":"1997"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.005_bib30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.005_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis. MRC centre for neuromuscular diseases, IBM workshop, London, 13 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","article-title":"International workshop on inclusion body myositis held at the institute of myology, paris, on 29 may 2009","volume":"20","author":"Benveniste","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.005_bib33","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, naarden, the Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib34","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"Dobloug","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/mus.27716","article-title":"Atypical presentations of inclusion body myositis: clinical characteristics and long-term outcomes","volume":"66","author":"Alamr","year":"2022","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.005_bib36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"van der Meulen","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.005_bib37","first-page":"340","article-title":"Two emerging phenotypes of atypical inclusion body myositis: illustrative cases","volume":"41","author":"Salam","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.005_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mus.24060","article-title":"Inclusion-body myositis presenting with facial diplegia","volume":"49","author":"Ghosh","year":"2014","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.005_bib39","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1007\/s00415-023-11878-w","article-title":"Inclusion body myositis with early onset: a population-based study","volume":"270","author":"Lindgren","year":"2023","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.005_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rdc.2025.07.005_bib42","article-title":"Measurement properties of the inclusion body myositis functional rating scale","author":"Salam","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.005_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acn3.51294","article-title":"Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies","volume":"8","author":"Ikenaga","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.rdc.2025.07.005_bib44","first-page":"27","article-title":"Muscle MRI for neuromuscular disorders","author":"Nicolau","year":"2020","journal-title":"Pract Neurol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/mus.24661","article-title":"Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis","volume":"52","author":"Tasca","year":"2015","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.005_bib47","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1212\/WNL.0000000000200776","article-title":"Longitudinal changes in MRI muscle morphometry and composition in people with inclusion body myositis","volume":"99","author":"Laurent","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.005_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1759720X12447705","article-title":"Novel approaches in the treatment of myositis and myopathies. Review","volume":"4","author":"Albayda","year":"2012","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.005_bib49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mus.26875","article-title":"Ultrasound can differentiate inclusion body myositis from disease mimics","volume":"61","author":"Leeuwenberg","year":"2020","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.005_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mus.26411","article-title":"Assessing the accuracy of neuromuscular ultrasound for inclusion body myositis","volume":"59","author":"Karvelas","year":"2019","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.005_bib52","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ultrasmedbio.2021.04.019","article-title":"Musculoskeletal ultrasound in inclusion body myositis: a comparative study with magnetic resonance imaging","volume":"47","author":"Guimaraes","year":"2021","journal-title":"Ultrasound Med Biol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.005_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13672","article-title":"NLRP3 inflammasome activation and altered mitophagy are key pathways in inclusion body myositis","volume":"16","author":"Naddaf","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:13:06Z","timestamp":1772853186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X25000523"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on Diagnostic Criteria of Inclusion Body Myositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}